| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Bone and Mineral Metabolism Laboratory, Research Unit, Fundación Jiménez Díaz, 28040 Madrid, Spain
Address all correspondence and requests for reprints to: P. Esbrit, Ph.D., Bone and Mineral Metabolism Laboratory, Research Unit, Fundación Jiménez Díaz, Avda. Reyes Católicos 2, 28040 Madrid, Spain. E-mail: pesbrit{at}fjd.es
Studies were undertaken to determine whether PTH-related protein
(PTHrP) (107139) mobilizes [Ca2+]i in
osteoblastic osteosarcoma UMR 106 cells. PTHrP (107139), in a manner
similar to PTHrP (107111), induced a rapid
[Ca2+]i response in these cells that was dose
dependent (EC50 of
0.1 pM) and more
efficient than that of PTHrP (136) (EC50 of
1
nM). This effect of PTHrP (107139) was abrogated by
micromolar doses of verapamil or nifedipine. However, it was unaffected
by 10 µM U73122 (a phospholipase C inhibitor), 100
µg/ml heparin (an inositol 1,4,5-trisphosphate receptor inhibitor),
or 400 ng/ml pertussis toxin (a Gi inhibitor), which
inhibited the [Ca2+]i response to PTHrP
(136), or by either 25 nM bisindolylmaleimide I (BIM), a
protein kinase (PK) C inhibitor, or 1 µM
phorbol-12-myristate-13-acetate preincubation (22 h). PTHrP (107139)
and PTHrP (136), at 100 nM, desensitized the
[Ca2+]i response to a second challenge with
the same peptide, but not with the other peptide in these cells. PTHrP
(734), a type 1 PTH/PTHrP receptor (PTH1R) antagonist, decreased the
effect of PTHrP (136) on [Ca2+]i. In
contrast, PTHrP (107111), but neither PTHrP (109138) nor PTHrP
(734), abolished this effect of PTHrP (107139). Both PTHrP
(107139) and PTHrP (136), added together at submaximal doses,
induced a higher [Ca2+]i response. Moreover,
PTHrP (107139) increased the efficacy of PTHrP (136) on
[Ca2+]i, but decreased its induced increase
in PKA activity in these cells. Verapamil or nifedipine (at 50
µM) or 25 nM BIM, but not 25 µM
adenosine 3',5'-cyclic monophosphorothioate, Rp-isomer, a PKA
inhibitor, abolished the PTHrP (107139)-induced increase in
interleukin 6 messenger RNA (assessed by RT, followed by PCR) in UMR
106 cells. This peptide also increased c-fos messenger
RNA in these cells; an effect inhibited by BIM, but unaffected by
either verapamil or EGTA. These findings support the existence of
high-affinity receptors for PTHrP (107139), associated with an
induced Ca2+ influx, different from the PTH1R in UMR 106
cells. The present results suggest that PTHrP could affect bone
turnover by interacting with the PTH1R and other yet unknown receptors
in bone cells through complex mechanisms.
This article has been cited by other articles:
![]() |
G.E. Wise, Y. Ren, and S. Yao Regulation of Osteoprotegerin Gene Expression in Dental Follicle Cells Journal of Dental Research, April 1, 2003; 82(4): 298 - 302. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, R. L. Duncan, D. B. Burr, V. H. Gattone, and C. H. Turner Parathyroid Hormone Enhances Mechanically Induced Bone Formation, Possibly Involving L-Type Voltage-Sensitive Calcium Channels Endocrinology, April 1, 2003; 144(4): 1226 - 1233. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Guillen, P. Martinez, A. R. de Gortazar, M. E. Martinez, and P. Esbrit Both N- and C-terminal Domains of Parathyroid Hormone-related Protein Increase Interleukin-6 by Nuclear Factor-kappa B Activation in Osteoblastic Cells J. Biol. Chem., July 26, 2002; 277(31): 28109 - 28117. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |